目的 :评价中等剂量左氧氟沙星用于肾移植术后预防及治疗感染的安全性及不良反应。方法 :回顾性分析 130例肾移植术后病人 ,其中 65例(男性 4 4例 ,女性 2 1例 ;年龄 4 4a±s 8a)采用左氧氟沙星 2 0 0mg ,iv ,gtt ,q 12h。另 65例 (男性 38例 ,女性 2 7例 ;年龄 4 2a± 11a)采用头孢噻肟 3g ,iv ,gtt ,q 12h ,为对照组。 2组疗程均为 7～ 14d。结果 :左氧氟沙星组治疗总有效率 95% ,切口Ⅰ期愈合率 97% ,不良反应发生率 5%。头孢噻肟组分别为 94 % ,95%和 6%。 2组差异无显著意义 (P >0 .0 5)。结论 :中等剂量的左氧氟沙星用于肾移植术后预防及治疗感染与头孢噻肟同样是安全可靠的 Objective: To evaluate the safety and adverse reactions of middling levofloxacin in prevention and treatment of infection after renal transplantation. Methods: A total of 130 renal transplant recipients were retrospectively analyzed. Totally 65 patients (44 males and 21 females; age 4 4a ± s 8a) received levofloxacin 200 mg, iv, gtt, q 12 hours. Another 65 patients (38 males and 27 females; age 4 2a ± 11a) were treated with cefotaxime 3g, iv, gtt, q 12h as the control group. 2 groups of treatment are 7 ~ 14d. Results: The levofloxacin group, the total effective rate was 95%, incision 97% rate of primary healing, the incidence of adverse reactions 5%. The cefotaxime group was 94%, 95% and 6%, respectively. There was no significant difference between the two groups (P> 0.05). CONCLUSIONS: Moderate-dose levofloxacin is equally safe and effective as cefotaxime for preventing and treating infections after renal transplantation